Literature DB >> 15099819

DNA damage induced by paclitaxel and DNA repair capability of peripheral blood lymphocytes as evaluated by the alkaline comet assay.

María Teresita Branham1, Silvina Beatriz Nadin, Laura María Vargas-Roig, Daniel Ramón Ciocca.   

Abstract

This study was designed to assess whether the chemotherapeutic drug paclitaxel can induce DNA damage in peripheral blood lymphocytes of human healthy donors, and to evaluate if such damage could be repaired. Venous blood was collected by routine venipuncture, the lymphocytes were isolated and cultured and then treated with 100nM, 500nM, 10microM, and 30microM of taxol for 4h. The alkaline comet assay technique was used to quantify the level of DNA damage and the DNA repair in lymphocytes. A significant increase in DNA damage was achieved when the cells were incubated with paclitaxel concentrations of 10microM or above. To test the DNA repair capability, the lymphocytes were allowed to recover for 2, 4, 6, and 24h. The DNA damage was almost completely repaired after 24h of incubation demonstrating a time-dependent repair capability. In conclusion, we demonstrate that paclitaxel induces DNA damage in peripheral blood lymphocytes and that this damage can be repaired.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099819     DOI: 10.1016/j.mrgentox.2004.01.013

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  19 in total

1.  Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.

Authors:  Gisela Natalia Castro; Niubys Cayado-Gutiérrez; Felipe Carlos Martín Zoppino; Mariel Andrea Fanelli; Fernando Darío Cuello-Carrión; Mayra Sottile; Silvina Beatriz Nadin; Daniel Ramón Ciocca
Journal:  Cell Stress Chaperones       Date:  2014-08-26       Impact factor: 3.667

2.  Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair.

Authors:  Jui-Ling Hsu; Pui-Kei Leong; Yunn-Fang Ho; Lih-Ching Hsu; Pin-Hsuan Lu; Ching-Shih Chen; Jih-Hwa Guh
Journal:  Cancer Lett       Date:  2012-01-17       Impact factor: 8.679

3.  Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).

Authors:  Lara E Sucheston; Hua Zhao; Song Yao; Gary Zirpoli; Song Liu; William E Barlow; Halle C F Moore; G Thomas Budd; Dawn L Hershman; Warren Davis; Gregory L Ciupak; James A Stewart; Claudine Isaacs; Timothy J Hobday; Muhammad Salim; Gabriel N Hortobagyi; Julie R Gralow; Robert B Livingston; Kathy S Albain; Daniel F Hayes; Christine B Ambrosone
Journal:  Breast Cancer Res Treat       Date:  2011-07-16       Impact factor: 4.872

4.  Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs.

Authors:  Cinzia Lucia Ursini; Delia Cavallo; Antonio Colombi; Margherita Giglio; Alessandro Marinaccio; Sergio Iavicoli
Journal:  Int Arch Occup Environ Health       Date:  2006-06-08       Impact factor: 3.015

5.  Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.

Authors:  Hiromi Inoue; Sung Hee Hwang; Aaron T Wecksler; Bruce D Hammock; Robert H Weiss
Journal:  Cancer Biol Ther       Date:  2011-11-01       Impact factor: 4.742

6.  Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.

Authors:  Gang Li; Jingfeng Zhao; Xianjing Peng; Jian Liang; Xin Deng; Yuxiang Chen
Journal:  Cancer Biother Radiopharm       Date:  2012-04-10       Impact factor: 3.099

7.  Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.

Authors:  Kuan-Chun Huang; Junzheng Yang; Michelle C Ng; Shu-Kay Ng; William R Welch; Michael G Muto; Ross S Berkowitz; Shu-Wing Ng
Journal:  Eur J Cancer       Date:  2016-09-24       Impact factor: 9.162

8.  The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.

Authors:  Laura Annovazzi; Valentina Caldera; Marta Mellai; Chiara Riganti; Luigi Battaglia; Daniela Chirio; Antonio Melcarne; Davide Schiffer
Journal:  Int J Oncol       Date:  2015-04-16       Impact factor: 5.650

9.  Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.

Authors:  Jessica Gillen; Austin Miller; Katherine M Bell-McGuinn; Russell J Schilder; Joan L Walker; Cara A Mathews; Linda R Duska; Saketh R Guntupalli; Roisin O'Cearbhaill; John Hays; Andrea R Hagemann; Heidi J Gray; Sarah W Gordon; Deborah K Armstrong; Alice Chen; Paula M Fracasso; Carol Aghajanian; Kathleen N Moore
Journal:  Gynecol Oncol       Date:  2021-02-17       Impact factor: 5.482

10.  Simultaneous Targeting Tumor Cells and Cancer-Associated Fibroblasts with a Paclitaxel-Hyaluronan Bioconjugate: In Vitro Evaluation in Non-Melanoma Skin Cancer.

Authors:  Barbara Bellei; Silvia Caputo; Emilia Migliano; Gianluca Lopez; Valeria Marcaccini; Carlo Cota; Mauro Picardo
Journal:  Biomedicines       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.